<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176395</url>
  </required_header>
  <id_info>
    <org_study_id>DH20140604</org_study_id>
    <nct_id>NCT02176395</nct_id>
  </id_info>
  <brief_title>Multi-&quot;Omics&quot; Research of Danhong Injection to Treat Acute Ischemic Stroke</brief_title>
  <official_title>Multi-&quot;Omics&quot; Research of Danhong Injection to Treat Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China Food and Drug Administration</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the pharmacological mechanism of Danhong injection in
      the treatment of acute ischemic stroke.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale 0-1 (favourable outcome) at Day 90</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>The changes of serum proteomics in 36 patients selected from certain center</measure>
    <time_frame>Day 0, Day 14, Day 90</time_frame>
    <description>We wish to identify protein biomarkers in the blood that changed with Danhong treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>The microRNA profile in 10 healthy volunteer</measure>
    <time_frame>Day0</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The mRNA profiles in 10 healthy volunteer</measure>
    <time_frame>Day0</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The proteomics profiles of 10 healthy volunteer</measure>
    <time_frame>Day 0</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Acute Stroke</condition>
  <arm_group>
    <arm_group_label>Danhong injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteer</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danhong injection</intervention_name>
    <description>40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion</description>
    <arm_group_label>Danhong injection</arm_group_label>
    <other_name>A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard medical care</intervention_name>
    <description>Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.</description>
    <arm_group_label>Danhong injection</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female or male inpatients

               -  Age: 18 - 70 years.

               -  Clinical diagnosis of ischemic stroke causing a measurable neurological deficit
                  defined as impairment of language, motor function, cognition and/or gaze, vision
                  or neglect. Ischemic stroke is defined as an event characterized by the sudden
                  onset of an acute focal neurologic deficit presumed to be due to cerebral
                  ischemia after CT scan excludes hemorrhage.

               -  Clinical diagnosis of &quot;Xueyu Zheng&quot; (Blood Stasis Syndrome) as the scores of
                  Chinese medicine symptoms scales of &quot;Xueyu Zheng&quot; in ischemic stroke ≥ 20. The
                  Chinese medicine symptoms scales of &quot;Xueyu Zheng&quot; is defined as following
                  (1)hemiplegia-10,(2)numbness of limbs-10，(3) dark face-9,(4)purple or dark
                  lip-8,(5)Roughness of skin-4, (6) pain with fixed point-5, (7) purple or dark
                  tongue-10,(8)ecchymosis on tongue-10,(9)purple sublingual vessel-10,(10)varicose
                  sublingual vessel-8,(11)unsmooth pulse-8,(12)intermittent pulse-1.

               -  Onset of symptoms in 1 week prior to initiation of administration of study drug.

               -  Clinical diagnosis of cerebral anterior circulation obstruction.

               -  4≤NIHSS＜20.

               -  Patient is willing to participate voluntarily and to sign a written patient
                  informed consent. Informed consent will be obtained from each patient or the
                  subject's legally authorized representative or relatives, or deferred where
                  applicable, according to the regulatory and legal requirements of the
                  participating centers.

          2. Female or male healthy volunteer

               -  Age: 18 - 70 years.

               -  Medical history, physical examination, vital signs, electrocardiogram(ECG) and
                  laboratory results (including renal function, hepatic function, et al)with no
                  clinically significant findings.

               -  Healthy volunteer is willing to participate voluntarily and to sign a written
                  informed consent form. Informed consent will be obtained from each volunteer,
                  according to the regulatory and legal requirements of the participating centers.

        Exclusion Criteria:

          1. Female or male inpatients

               -  Evidence of intracranial hemorrhage (ICH) or other cerebral diseases (eg.vascular
                  malformation, tumor, abscess or multiple sclerosis etc.)on the CT-or MRI-scan.

               -  Patients with thrombolysis or endovascular treatment.

               -  Known history of allergy or suspected allergic to the drug.

               -  Blood glucose 2.8 or &gt; 16.8 mmol / l under the treatment of diabetes or with
                  severe complications due to diabetes (eg. peripheral neuropathy, diabetic
                  gangrene).

               -  Liver function impairment with the value of ALT or AST over 1.5-fold of normal
                  value.

               -  Renal dysfunction with the value of serum creatinine over 1.5-fold of normal
                  value.

               -  Severe cardiac dysfunction on echocardiogram or the grade of heart function over
                  Ⅲ grade.

               -  History of prior stroke with mRS ≥2.

               -  Complicated with atrial fibrillation.

               -  Severe stroke as assessed by appropriate imaging techniques (eg. massive cerebral
                  infarction including more than one lobe of brain or over 1/3 of blood-supply area
                  of middle cerebral artery).

               -  Prior disable patients.

               -  Hemorrhagic tendency or recent severe or dangerous bleeding in 3 months.

               -  Suspected addicted into alcohol or drug abuse.

               -  With severe complications that would make the condition more complicated assessed
                  by the investigator.

               -  Woman with pregnancy, lactation or positive result of pregnancy test, or women
                  who want to be pregnant in recent 6 months.

               -  Woman who is under menstrual period.

               -  Patient who is participating in other trials or has been participated in other
                  trials in recent 3 months.

          2. Healthy volunteer

               -  Had a known history of chronic diseases including stroke, heart diseases,
                  diabetes, COPD, Neuropsychiatric diseases and chronic infectious diseases, etc.

               -  Coagulation disorders.

               -  Conditions with increased bleeding risk.

               -  Trauma or surgery in the 6 months prior to the study.

               -  Use of any medication 4 weeks prior to the trial.

               -  History of drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang Zhong, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhao Xingquan, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wang Yongyan, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiang Zhilin, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>202 Military Hospital of China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>202 Military Hospital of China</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zhong Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Acute Ischemic Stroke</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Traditional Chinese Medicine</keyword>
  <keyword>Proteomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

